Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-66 (IGHV3-66)
- Target
- IGHV3-66
- Molecular classification
- Immunoglobulin gene segment, variable region of immunoglobulin heavy chain, Ig heavy chain V region, Other
01
Overview
Immunoglobulin heavy variable 3-66 (IGHV3-66) is a gene segment encoding the variable region of the immunoglobulin heavy chain, crucial for the diversity of antibody specificity. It is one of ~129 variable gene segments in the IGH locus on chromosome 14 and undergoes V(D)J recombination during B-cell development, forming part of the antigen-binding site in immunoglobulins. IGHV3-66 is expressed in B-lymphocytes, and the encoded protein participates in antigen recognition, forming the structural basis for the adaptive immune response. Polymorphisms in IGHV3-66 and allelic usage affect antibody diversity and can influence susceptibility to immune-mediated diseases such as Kawasaki disease. While not a direct drug target, IGHV3-66’s encoded antibodies (e.g. in monoclonal antibody therapies) may be relevant in infectious disease treatment and immune diagnostics.
- Other names
- Immunoglobulin heavy chain variable region 3-66IGHV3-66IGHV366HV366immunoglobulin heavy variable region
02
Mechanism of action
When used in therapeutic antibodies, the mechanism is antigen binding, neutralization, or opsonization dependent on antibody specificity
03
Biological functions
Antigen recognition and bindingHumoral immune response (antibody generation)Clonal expansion and affinity maturation (part of B-cell function)
04
Disease associations
Infection (participates in antibody defense against pathogens)Complex genetic diversity relevant in Kawasaki disease susceptibilityVariability may contribute to autoimmunity and other immunological disorders
05
Safety considerations
No specific safety concerns for IGHV3-66 as a gene; therapeutic antibodies using this sequence may share class-wide concerns such as immunogenicity, off-target effects, or cytokine release syndrome
06
Interacting drugs
None directly; IGHV3-66 is not directly targeted by drugs, but monoclonal antibodies constructed using this heavy chain variable region can have therapeutic applications (e.g., certain SARS-CoV-2 neutralizing antibodies are IGHV3-66 encoded)
07
Biomarkers
IGHV3-66 gene usage or allelic expression may serve as a biomarker for certain immune responses or disease predisposition (e.g., Kawasaki disease association)
Beyond the preview
Go deeper on Immunoglobulin heavy variable 3-66 (IGHV3-66).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy variable 3-66 (IGHV3-66).